The Rise of a 'Miracle' Drug
GLP-1 receptor agonists are not new; drugs like semaglutide (sold as Ozempic and Wegovy) and liraglutide (Saxenda) were first developed to manage type 2 diabetes. They work by mimicking a gut hormone that signals fullness to the brain, slows stomach emptying
and regulates blood sugar. Their remarkable side effect—significant weight loss—has led to their widespread adoption for obesity management in adults. Clinical trials have confirmed their effectiveness, with some users losing over 15% of their body weight, prompting approvals for weight management and a surge in popularity worldwide.
A New Hope for Teenagers?
With childhood and adolescent obesity rates quadrupling since 1990, affecting an estimated 170 million young people globally in 2024, the search for effective treatments is urgent. In this context, GLP-1 drugs have shown promise. Studies have demonstrated that adolescents aged 12 and older can achieve significant weight loss, with some trials showing an average reduction of 16% of body weight. This has led to approvals in some countries for teens with obesity, offering a potential medical tool for a condition that carries risks of type 2 diabetes, heart disease, and severe mental health challenges from bullying and stigma.
Why the WHO Says 'Slow Down'
Despite the promising results, the WHO's first-ever global guidelines on childhood obesity management, released in October 2026, take a decidedly cautious stance. The primary message is that medication should not be the first-line treatment. For adolescents aged 10-19, the WHO recommends that drugs like GLP-1s only be considered after a comprehensive, supervised program of diet, physical activity, and behavioural therapy has failed to produce results. For children under 10, the organisation recommends against these drugs entirely. This contrasts with its 2025 guidelines for adults, which were more open to including these medicines as part of a broader care plan.
The Long-Term Unknowns
The WHO's caution is rooted in a major evidence gap: the lack of long-term data. Adolescence is a critical period of physical and psychological development, and experts have raised crucial questions. What is the impact of appetite-suppressing medication on a growing body's hormonal balance, bone development, and muscle mass? What are the consequences of using a drug that affects brain receptors while the brain is still maturing? There are also concerns about potential nutritional deficiencies and the development of eating disorders. Furthermore, studies show that when adults stop taking these drugs, they often regain the weight, suggesting that adolescents who start them might need them for life, a costly and medically intensive prospect.
A Tool, Not a Panacea
Experts, including those at the WHO, agree that obesity is a complex, chronic disease, not a simple matter of willpower. The new guidelines stress a 'person-centered' approach where medicine is, at best, a single tool in a much larger toolbox. The foundation of care remains lifestyle modification, including healthy eating, physical activity, and sustained behavioural change, supported by family and healthcare providers. Mental health support is also deemed critical. The WHO's position is not a complete rejection of these drugs for teens but a strong reminder that they are a last resort, to be used only under strict supervision and when the young person is physically and psychologically prepared.
